Kexing Biopharm (688136.SH): The first participant in the Phase I clinical trial of GB10 injection has completed dosing.

19:53 13/05/2026

Covax Pharmaceuticals (688136.SH) announced that recently, its wholly-owned subsidiary Shenzhen Covax Pharmaceutical Co., Ltd. ("Shenzhen Covax") has successfully completed the first dose administration of the first subject in the Phase I clinical trial of the ophthalmic preparation "GB10 Injection" independently developed by itself.

Kexing Biopharm (688136.SH) announced that recently, its wholly owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. ("Shenzhen Kexing") completed the first dosing of the first subject in the Phase I clinical study of the ophthalmic preparation "GB10 Injection" developed independently by Shenzhen Kexing. It is reported that Shenzhen Kexing's GB10 Injection is currently conducting a Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and effectiveness of GB10 in patients with neovascular age-related macular degeneration (nAMD). The first dosing of the first subject was successfully completed recently.

XXF (02473) plans to offer a discount of about 2.38% in a rights issue, with a net proceeds of approximately HK$1.26 billion.

Hansoh Pharma (03692): HS-10541 tablets obtained the drug clinical trial approval notification letter issued by the National Medical Products Administration.

CF PHARMTECH (02652) spent HK$344,000 to repurchase 16,500 shares on May 13th.

XXF (02473) plans to offer a discount of about 2.38% in a rights issue, with a net proceeds of approximately HK$1.26 billion.

Hansoh Pharma (03692): HS-10541 tablets obtained the drug clinical trial approval notification letter issued by the National Medical Products Administration.

CF PHARMTECH (02652) spent HK$344,000 to repurchase 16,500 shares on May 13th.